Tapinarof

(Vtama®)

Tapinarof

Drug updated on 6/25/2024

Dosage FormCream (topical; 1%)
Drug ClassAryl hydrocarbon receptor agonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the topical treatment of plaque psoriasis in adults.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated, with no liability accepted for reliance on it. Learn more.

  • Tapinarof (Vtama) is indicated for the topical treatment of plaque psoriasis in adults, showing superior efficacy to both placebo and calcipotriol across 2,408 patients in eight clinical studies.
  • The information was derived from five systematic reviews/meta-analyses focusing on Tapinarof (Vtama) for the topical treatment of plaque psoriasis and atopic dermatitis.
  • Despite a higher incidence of adverse events compared to placebo and calcipotriol, serious systemic adverse events were not reported with Tapinarof (Vtama) use, marking it as a safe treatment option.
  • In comparison with benvitimod, another topical drug for psoriasis and atopic dermatitis involving 1,925 patients' studies, Tapinarof (Vtama) showed similar effectiveness but potentially safer or comparable safety profile under certain conditions due to absent data on serious adverse events.
  • Among emerging treatments such as crisaborole and systemic therapies focusing on Janus kinase inhibitors targeting various interleukins for Atopic Dermatitis (AD), Tapinarof's (Vtama) unique mechanism provides an alternative route expanding the arsenal of available treatments.
  • While not directly compared in trials against other drugs like crisaborole or ruxolitinib treating mild-to-moderate AD cases; insights suggest that all three present statistically significant improvements in disease severity with well-tolerated profiles positioning Tapinarof (Vtama) competitively within this landscape.